We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Genedata Unveils Computational Solution Genedata Expressionist®

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Genedata has announced the release of Genedata Expressionist® Pro 3.0, a versatile computational solution for omics data integration, processing and analysis.

The software system now adds support for proteomics- and metabolomics-based biomarker studies and exploits a client-server architecture for rapid processing of mass spectrometry data.

"We have successfully tackled the challenging problem of technology integration in the MS field," explained Adesh Kaul, Business Head of Genedata Expressionist.

MS-based proteomics and metabolomics data is generated with a combination of separation and measurement technologies that come in many different configurations.

Genedata has developed a generic MS data framework that supports a variety of different MS platforms and uses Expressionist’s automated workflows for processing and analysis.

Expressionist’s automated processing of raw chromatogram data provides a means to perform sensitive, high throughput biomolecular profiling.

The software is designed to facilitate integration of MS results with protein sequence search engine results and with genomic and transcriptomic information.

These features combine to form an end-to-end MS solution for integrating proteomic and metabolomic data with other biomolecular results.

"Expressionist now delivers a MS solution boasting the same standard of statistical validation and automation as our solution for microarray and gel based omics technologies," says Dr. Daniel Keesman, CEO of Genedata.

"Standardization and automation are pre-conditions for successful biomarker discovery efforts that combine proteomic, metabolomic and transcriptomic data."